Why “More Data” Isn’t Helping You Run Better Trials


April 28, 2026

Clinical Operations teams are being asked to let go of traditional approaches and do more than ever before:

Deliver more complex trials, faster — with fewer resources — and higher confidence in outcomes.

And how has the industry responded?

With a proliferation of data access, tools, and dashboards.  But does a dashboard really help navigate complexity with speed and well-managed risk?  No.

Let’s discuss the methods and tools that help turn this complexity into clarity.

 

The problem isn’t just complexity — It’s information overload

Clinical trials have changed dramatically:

  • 7x increase in data points
  • 4x increase in data sources
  • Increasing reliance on external data, RWE, and predictive modeling

Yet often you’re still expected to manage across multiple systems, in spreadsheets and trackers: CTMS, EDC, RBQM dashboards, query reports, enrollment trackers, deviation logs, and monitoring reports.

None of these disparate sources of information tell the whole story, and every critical study execution decision you make is plagued with data gaps, inconsistencies or discrepancies, and latency issues.

How then can we consolidate and automate our use of the data to make timely decisions that we trust?  There are certainly technology stacks that large organizations license and deploy.  But what happens when you can’t afford them?  You partner with a data management and biometrics specialty provider who understands what you are up against, what is needed to successfully deliver a study, who understands the data and what is required, and who offers critical solutions to help heads of clinical operations gain control at a price that they can afford.

Tools that actually make a difference offer:

  • Actionable insights, not static reports
  • Continuous visibility, not retrospective analysis
  • Aligned teams, not handoffs

 

Central statistical monitoring: Detecting emerging risks early

Early intervention is key to managing trial risks and ensuring reliable results. As clinical trials grow in complexity, data quality and patient safety can no longer be ensured within system reports. And with evolving regulatory expectations, trial budget pressures, and the need for earlier, more objective insights into emerging risks, central statistical monitoring (CSM) has become a critical component of modern trial oversight.

Tools, such as Cytel’s Cytelytics, can leverage statistics to identify trends, detect risks, and optimize source data verification efforts.

Regulatory agencies now treat audit trail data with the same level of scrutiny as clinical data, and expect proactive, ongoing reviews. Relying on outdated or manual approaches is a risk you can’t afford.

Additionally, regulatory agencies emphasize the need for proactive and ongoing audit trail reviews, treating audit trail data with the same level of scrutiny as clinical data. Manual approaches are time sinks and can introduce unnecessary risk. Tools like Cytel’s Audit Detective enhance compliance and data integrity by identifying inconsistencies, unauthorized access, and unusual activity patterns in audit trails.

 

Better data visualization: Driving decisions, not just reporting

Traditional reports tell you what happened. Modern visualization:

  • Links operational metrics to clinical outcomes
  • Allows drill-down from summary to patient level
  • Highlights where intervention changes the outcome

Tools like Cytel’s ClinCytesDV provides interactive graphs, tables, and listings, layering data together to tell a richer story.

 

Data management: Operating environments that drive speed and quality

Data ingestion, cleaning, reconciliation, and reporting should not operate in lock step. A modern approach:

  • Automates data ingestion across sources (EDC, RWD, wearables)
  • Standardizes data structures (CDISC, OMOP, FHIR)
  • Enables real-time cleaning and review

The result is better data processing, reduced site burden, faster lock — and less firefighting. This is the difference between oversight and control.

 

Final takeaways

The answer isn’t more dashboards, systems, or data, but rather the methods and tools that result in fewer reconciliations across systems, earlier visibility into risks, faster decisions with higher confidence, and ultimately, that allow you to spend less time managing the process — and more time managing the study.

Contact Us!
Subscribe to our newsletter

Michelle Hoiseth

Senior Vice President, General Manager of ​Project Based Analytical Services

Michelle has 35+ years of clinical research experience in a range of capacities including ​​data management, project management, portfolio management, strategic partnerships, and business leadership. Her experiences creating complete product development plans, designing novel regulatory pathways to approval, writing both strategic and tactical business development plans, and supporting ​​product commercialization objectives and lifecycle management have provided her with a well-grounded perspective on the business of clinical development.

Michelle is a thought leader in the industry with publications in peer-reviewed and industry journals on the topics of study design, safety/efficacy, data interoperability and the application of emerging technologies to ​advanced analytics. She is focused on establishing new approaches and methods in the development of clinical therapies, with a commitment to improve human health. Michelle stands for developing inclusive, innovative, invested teams that bring their very best to the advancement of therapeutics – something that, here at Cytel, we are strongly invested in.

Read full employee bio

Claim your free 30-minute strategy session

Book a free, no-obligation strategy session with a Cytel expert to get advice on how to improve your drug’s probability of success and plot a clearer route to market.

glow-ring
glow-ring-second